The introduction of 2-[
18 F]Fluoro-2-deoxy-D-glucose (FDG) and PET imaging in routine use at the end of the 1990s was a real breakthrough in the field of nuclear medicine. It opened the way to innovative functional imaging, complementary to morphological conventional imaging such as ultrasonography, CT and MRI. For more than a decade, FDG has been the unique PET radiopharmaceutical available in oncology. FDG brings useful information in many clinical indications for tumor staging, tumor aggressiveness assessment and monitoring of response to treatment. This is why PET/CT with FDG is now considered as the reference standard for imaging in oncology. However, despite its noteworthy advantages, FDG has some practical limitations and does not bring information on important tumor functions such as apoptosis, hypoxia, angiogenesis etc. Other 18 F-labeled tracers have been tested in clinical applications where FDG is not optimal. For instance, to discuss oncology only, fluoro-ethyl-tyrosine and fluoro-dopamine show better sensitivity than FDG in brain tumors. Fluoro-choline may be used in prostate cancer, where FDG lacks sensitivity. Fluoro-estradiol may image ER + brain tumors. F-MISO is proposed for hypoxia imaging, but with rather poor contrast ratios. PET imaging with 18 F-fluoride is presented as an alternative to classical bone scintigraphy with 99m Tc-labeled radiopharmaceuticals. Thus there is a need for alternative radiopharmaceuticals with different carriers and different positron-emitting radionuclides, since the short half-life of 18 F results in a rather expensive supply chain and may be too short for some applications. Tens, if not hundreds, of carrier molecules labeled with a limited number of original positron-emitting radionuclides have been evaluated in preclinical studies. In this context, a "Workshop on Innovative Positron Emitting Radionuclides (WIPR)" was organized in Nantes, France, in July 2010, during which more advanced preclinical and clinical studies were presented with a view to help selecting radionuclides more likely to be approved on a short-to medium-term time scale.
Preclinical and clinical PET imaging
Alain Le Pape, from Orléans, presented recent progress in instrumentation and experimentation methodology for preclinical studies. A variety of micro-PET devices that may be coupled to CT-scanners are now available. These instruments will advance the development of new PET imaging radiopharmaceuticals by providing preclinical proofs of concepts. Françoise Kraeber-Bodéré, from Nantes, presented new advances in the use of FDG in various clinical situations, depicting the role of FDG in prognostication and monitoring tumor response to chemotherapy and radioimmunotherapy. She emphasized clinical needs, particularly around functional and phenotypic imaging, for which radionuclides other than 18 F will be needed.
Gallium-68
Gallium-68, produced from a generator 68 Ge/ 68 Ga, is one of the most promising of such alternative positron-emitting radionuclides with its daily availability for a few months and the relatively easy labeling of a large number of small carrier molecules such as peptides which have fast pharmacokinetics, fitting well to the short half-life of 68 
Copper-64
Copper-64 is another promising positron-emitting radionuclide. It was produced previously in a nuclear reactor with low specific activity. However, following the 64 Ni( p, n) 64 Cu reaction, suggested by the Jülich group, it is now easily produced by low energy cyclotrons. Its half-life (12.7 h), longer than that of 68 Ga, allows the labeling of many carrier molecules and shipment to places relatively far from the production site. The use of 64 Cu for molecular imaging was reviewed by C. J. Anderson. There are many possibilities to couple 64 Cu to vectors. Which one is the best remains a matter of debate, and research for even better solutions is being very actively followed, as shown by A. Lecointre et al. and by H. Rajerison et al. One carrier molecule, a thiosemicarbazone, is particularly interesting because it is a copper chelating agent that is trapped into hypoxic areas of tumors. It has been developed by researchers in Saint Louis Mallinckrodt Institute in the USA and successfully tested in patients. It gives a much higher tumor-to-muscle ratio than 18 F-MISO, making the interpretation of images much easier. A clinical phase II, sponsored by National Institutes of Health (NCI) in USA, is ongoing in patients with cervical cancer. It aims at showing the bad prognostic value of positive PET tumor images and the need for adding a dose boost on hypoxic tumor areas. Such a radiopharmaceutical is highly requested for external beam radiotherapy and could help improving clinical effectiveness in tumors that tend to be hypoxic, such as head and neck, lung or prostate cancers. Progress with such thiosemicarbazone compounds was discussed by M. Christlieb et al.
Iodine-124
Iodine-124 is a very important positron-emitting radionuclide and it is already finding many applications. As a radiohalogen it can be easily attached to organic molecules via the analogue approach, also considering that relatively vast experience is available through the use of two other radiohalogens, namely 123 I for diagnosis and 131 I for therapy. Regarding the clinical use of 124 I, in recent years several workshops have been organized. This radionuclide is generally produced via the low-energy nuclear reaction 124 Te( p, n) 124 I on highly enriched target material, mainly developed at Jülich. The yield is rather low but the radionuclidic purity is high. The half-life of 124 I is somewhat long (4.2 d), the positron energy is relatively high, and several γ -rays are also emitted in the decay. Consequently some radiation safety constraints are required from regulatory authorities, at least in Europe, for a routine use of this radionuclide. During the present Workshop, not much attention was given to this radionuclide, since the emphasis was more on metallic positron-emitting radionuclides. 
Yttrium-86

Zirconium-89
Zirconium-89 is another potentially useful positron-emitting radionuclide. It has a relatively long half-life of 3.3 d, which is favorable for labeling of large carrier molecules such as antibodies with slow kinetics extending over a few days. D. Vugts presented the use of 89 Zr to track monoclonal antibodies in the human body (Immuno-PET). However, this radionuclide has some limitation regarding routine clinical use due to associated gamma emission with relatively high energy and high abundance (909 keV, 99.04%). 44 Sc is also interesting from the perspective of a 3-photon imaging technology which is presently under development. In addition, 44 Sc can be directly produced at cyclotrons together with 44m Sc, which has a much longer half-life of 58.6 h and could serve as an in vivo generator of 44 Sc, provided the complex remains stable after the internal transition from 44m Sc to 44 Sc.
Scandium-44
Production of PET radionuclides and other issues
The production and purification of innovative positron-emitting radionuclides is obviously a very important aspect of their future development. Syed M. Qaim from Jülich shared with the audience his broad experience and expertise on the development of novel PET radionuclides. The work entails interdisciplinary studies comprising nuclear data measurement, high-current target development and efficient chemical processing of the irradiated material. The basic production methodology for most of the innovative positron emitters, among them 64 Cu, 86 Y, 94m Tc, 120 I and 124 I, was developed at Jülich using the ( p, n) reaction on a suitable highly enriched target isotope at a small cyclotron (E < 20 MeV). This calls upon great efforts regarding the recovery of the rather expensive enriched target material. The only exceptions are 45 Ti and 89 Zr where the target elements ( 45 Sc and 89 Y) are moniosotopic. It was shown that a few high energy reactions give higher yields of the above mentioned positron emitters but the level of the radioactive impurities is generally also high. Due to this reason, presently even large scale production of most of the innovative positron emitters is envisaged and performed at small cyclotrons. The final aspect in the process of developing a new radiopharmaceutical is the procedure for market approval, which was illustrated with the example of 68 Ga by C. Decristoforo, representing the Radiopharmacy Committee of EANM.
Concluding remarks
As pointed out in the closing keynote lecture presented by Suresh Srivastava, the evolution of nuclear medicine started with empirically prepared radiopharmaceuticals in the past and has now reached the stage of present intelligent designing of agents for molecular imaging. A variety of biological vehicles will serve as specific carriers to deliver imaging positron-emitting radionuclides to diagnose diseases in oncology, cardiology and neurology. In addition to 18 F, currently available for routine use, a limited number of new radionuclides will end up with the required combination of favorable physical and biological characteristics to become useful on a routine basis. There is no doubt that functional PET imaging will continue to grow rapidly in the coming years and will complement the conventional morphological imaging techniques.
Finally, we appreciate the initiative of our colleague Sandrine Huclier-Markai, and the support of Syed M. Qaim, the Co-ordinating Editor of Radiochimica Acta, to publish a few selected papers from the Workshop in that journal. The participants were invited to submit written contributions which were peer-reviewed. The papers accepted are put together in this special issue of the journal.
